



US Patent Issued

November 11, 2020

Tanvex is pleased to announce that the United States Patent & Trademark Office has issued US patent number 10,703,800, titled "Cell Culture Medium". The patent will expire on March 31, 2038.

This patent is for the use of lithium ions in the cell culturing process to modulate polypeptide glycosylation profiles.

This invention is used in our TX05 and TX16 biosimilar products to, among other things, improve the glycosylation profile of the products.

TX05 is a proposed biosimilar to Herceptin® (trastuzumab). Tanvex is planning to submit a Biologics License Application (BLA) for TX05 to the US FDA in mid-2021. TX16 is a proposed biosimilar to Avastin® (bevacizumab). Tanvex has completed Phase I clinical trials for TX16 and has initiated planning for Phase III clinical trials.

About Tanvex

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.